Sep 17, 2021 06:55 PM IST
Biocon and SII are exploring development and commercialisation of SII's biologic portfolio, considering manufacture of raw materials for vaccines and biologics, and plan to develop and make drugs and vaccines based on mRNA platform.
- Apr 26, 2021 10:31 AM IST
The nod came following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, it said.
- Jan 07, 2021 05:05 PM IST
The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon
- Nov 24, 2020 12:21 PM IST
If the negotiations fructify— coming two weeks after the Goldman Sachs deal—it would mark the fourth successive investment in the Kiran Mazumdar Shaw-led Biocon unit in 2020.The last fundraise was struck at a valuation of $3.94 billion.
- Nov 07, 2020 04:04 PM IST
As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions
- Aug 03, 2020 12:58 PM IST
Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.
- Jul 31, 2020 12:25 PM IST
The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion
- Jul 21, 2020 11:30 AM IST
The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.
- May 12, 2020 02:10 PM IST
Biocon on Tuesday said its arm Biocon Biologics has received EU Good Manufacturing Practice (GMP) certification for its biologics drug substance facilities in Bengaluru.
- Apr 16, 2020 10:15 AM IST
The inspection was conducted between September 10 and September 19, 2019, a company spokesperson said, adding, Biocon Biologics has responded to the regulator on the eight observations from this inspection, in October last year.
- Jan 07, 2020 08:02 PM IST
Syngene, which was listed in August 2015, raised Rs 550 crore. The IPO was subscribed 32 times. Incidentally, True North was an investor in Syngene before it was listed.
- Jan 06, 2020 04:16 PM IST
Biocon said it would use the proceeds of stake sale for expansion of R&D and manufacturing capabilities.